Cogent Biosciences (COGT) Equity Average (2018 - 2026)

Cogent Biosciences' Equity Average history runs 9 years deep, the most recent figure standing at $622.0 million for Q1 2026.

• In Q1 2026, Equity Average rose 161.75% year-over-year to $622.0 million; the TTM figure through Mar 2026 stood at $622.0 million (up 161.75% YoY), while the FY2025 annual figure was $446.3 million, up 73.64% from the prior year.
• Equity Average was $622.0 million for Q1 2026 at Cogent Biosciences, up from $469.4 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $622.0 million in Q1 2026 to a low of $187.0 million in Q2 2025.
• Historically, Equity Average has averaged $310.3 million across 5 years, with a median of $285.5 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Equity Average plunged 52.99% in 2025, then surged 161.75% in 2026.
• A 5-year view of Equity Average shows it stood at $272.8 million in 2022, then grew by 2.75% to $280.3 million in 2023, then gained by 1.83% to $285.5 million in 2024, then surged by 64.44% to $469.4 million in 2025, then surged by 32.51% to $622.0 million in 2026.
• The last three Equity Average figures came in at $622.0 million (Q1 2026), $469.4 million (Q4 2025), and $228.8 million (Q3 2025), per Business Quant data.